In a nutshell The authors evaluated the prevalence and management of urethral blockage following certain cancer treatments. Some background Urethral stenosis is a medical condition characterized by a blockage in the urethra, the tube which drains fluid from the bladder to the outside of the body. The point of the blockage is referred to...
Read MoreTreatment(s) already received-Radical prostatectomy Posts on Medivizor
Linking the number of metastases to outlook in prostate cancer
In a nutshell This study attempted to examine the contribution of different components of prostate cancer on the outlook of patients diagnosed with metastatic disease despite treatment. Some background In some cases of prostate cancer, the primary treatment does not cure the disease, and metastases (cancer lesions in other body parts)...
Read MoreIs early adjuvant radiotherapy associated with different outcomes compared to delayed therapy?
In a nutshell The authors evaluated the optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. Some background Radical prostatectomy (surgery to remove the prostate) remains the most common treatment for localized prostate cancer (has not spread beyond the prostate)...
Read MoreWill postoperative radiation decrease the likelihood of prostate cancer recurrence?
In a nutshell This study examined the safety and efficacy of radiation therapy to the prostate bed and pelvic lymph nodes following surgery for prostate cancer. Some background Postoperative radiation therapy is a standard treatment for prostate cancer patients who are at an increased risk for recurrence (return of the disease even...
Read MoreStarting salvage radiotherapy early
In a nutshell This study evaluated the results of early salvage radiation therapy (ESRT) in prostate cancer patients after radical prostatectomy. Some background Following radical prostatectomy (surgical removal of the prostate gland), prostate cancer often recurs and requires further treatment. Surveillance for cancer recurrence is usually...
Read MoreTime from surgery to recurrence and how it affects survival
In a nutshell This study looked at men who had their prostate removed after diagnosis of prostate cancer. The study evaluated the time from surgery to biochemical recurrence, and whether this period of time is associated with survival or certain cancer characteristics. Some background One of the initial treatments for prostate cancer is a radical...
Read MoreRisk of disease progression in prostate cancer patients with biochemical recurrence after prostatectomy
In a nutshell This article reviewed the long-term risks associated with biochemical recurrence (BCR) in prostate cancer (PCa) patients after prostatectomy. It also evaluated different factors that predict cancer progression and cancer-specific deaths. Some background Many PCa patients are treated with surgery to remove all or part of the...
Read MoreComparing the benefits of radiotherapy versus a “wait and see” approach for patients with stage III prostate cancer who were treated with radical prostatectomy
In a nutshell The present study evaluated whether patients with stage III prostate cancer (PCa) who underwent radical prostatectomy (RP) would benefit from further radiotherapy (RT), as opposed to the "wait and see" approach. There was a 21% increase in survival with no cancer progression in patients who received additional RT. Some...
Read MoreNovel Therapies for Castration-Resistant Prostate Cancer
In a nutshell The present article reviews new and prospective treatments for castration-resistant prostate cancer (CRPC). Sipuleucel-T, Cabazitaxel, Denosumab and Abiraterone are novel therapies approved in the last few years for CRPC, while several other therapeutic agents such as MDV3100, Alpharadin and...
Read MoreEvaluating the toxicity of a new immune-based treatment for advanced prostate cancer – a clinical trial
The present clinical trial evaluated the safety of an immune-based therapy (termed ‘combined immunotherapy’) as an alternative to chemotherapy for the treatment of metastatic (spread with distant metastases) prostate cancer non-responsive to hormonal treatment, or ‘castration-resistant prostate cancer’ (mCRPC). The trial aimed...
Read MoreDenosumab: decrease in spread of bone cancer in men with prostate cancer (not responsive to hormone therapy & surgery)
In a nutshell The present study assessed the efficiency of a drug named Denosumab in delaying the spread of prostate cancer to the bone in men with resistant prostate cancer (not responding to hormone therapy and surgery). The results show that the drug tested delayed bone involvement by few months. Some background Bone metastases are...
Read MoreTreatment options for localized prostate cancer – comparing long-term adverse effects
In a nutshell This study aimed to identify health-related decline in quality of life 4 to 8 years after prostate cancer (PC) treatment. Main finding: measures of quality of life vary based on therapy choice. Some background Treatments for localized PC (confined to the prostate gland) include radical prostatectomy (RP), brachytherapy (BT) and...
Read More